BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 12948861)

  • 21. Effects of disease-modifying antirheumatic drugs and antiinflammatory cytokines on human osteoclastogenesis through interaction with receptor activator of nuclear factor kappaB, osteoprotegerin, and receptor activator of nuclear factor kappaB ligand.
    Lee CK; Lee EY; Chung SM; Mun SH; Yoo B; Moon HB
    Arthritis Rheum; 2004 Dec; 50(12):3831-43. PubMed ID: 15593184
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Activin A stimulates IkappaB-alpha/NFkappaB and RANK expression for osteoclast differentiation, but not AKT survival pathway in osteoclast precursors.
    Sugatani T; Alvarez UM; Hruska KA
    J Cell Biochem; 2003 Sep; 90(1):59-67. PubMed ID: 12938156
    [TBL] [Abstract][Full Text] [Related]  

  • 23. IL-6, leukemia inhibitory factor, and oncostatin M stimulate bone resorption and regulate the expression of receptor activator of NF-kappa B ligand, osteoprotegerin, and receptor activator of NF-kappa B in mouse calvariae.
    Palmqvist P; Persson E; Conaway HH; Lerner UH
    J Immunol; 2002 Sep; 169(6):3353-62. PubMed ID: 12218157
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adrenergic stimulation of osteoclastogenesis mediated by expression of osteoclast differentiation factor in MC3T3-E1 osteoblast-like cells.
    Takeuchi T; Tsuboi T; Arai M; Togari A
    Biochem Pharmacol; 2001 Mar; 61(5):579-86. PubMed ID: 11239501
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Microrough implant surface topographies increase osteogenesis by reducing osteoclast formation and activity.
    Lossdörfer S; Schwartz Z; Wang L; Lohmann CH; Turner JD; Wieland M; Cochran DL; Boyan BD
    J Biomed Mater Res A; 2004 Sep; 70(3):361-9. PubMed ID: 15293309
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 1,25(OH)2 vitamin D3-stimulated osteoclast formation in spleen-osteoblast cocultures is mediated in part by enhanced IL-1 alpha and receptor activator of NF-kappa B ligand production in osteoblasts.
    Lee SK; Kalinowski J; Jastrzebski S; Lorenzo JA
    J Immunol; 2002 Sep; 169(5):2374-80. PubMed ID: 12193704
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Roles of stromal cell RANKL, OPG, and M-CSF expression in biphasic TGF-beta regulation of osteoclast differentiation.
    Karst M; Gorny G; Galvin RJ; Oursler MJ
    J Cell Physiol; 2004 Jul; 200(1):99-106. PubMed ID: 15137062
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Transforming growth factor beta affects osteoclast differentiation via direct and indirect actions.
    Quinn JM; Itoh K; Udagawa N; Hausler K; Yasuda H; Shima N; Mizuno A; Higashio K; Takahashi N; Suda T; Martin TJ; Gillespie MT
    J Bone Miner Res; 2001 Oct; 16(10):1787-94. PubMed ID: 11585342
    [TBL] [Abstract][Full Text] [Related]  

  • 29. NF-kappaB p50 and p52 expression is not required for RANK-expressing osteoclast progenitor formation but is essential for RANK- and cytokine-mediated osteoclastogenesis.
    Xing L; Bushnell TP; Carlson L; Tai Z; Tondravi M; Siebenlist U; Young F; Boyce BF
    J Bone Miner Res; 2002 Jul; 17(7):1200-10. PubMed ID: 12096833
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reciprocal gene expression of osteoclastogenesis inhibitory factor and osteoclast differentiation factor regulates osteoclast formation.
    Nagai M; Sato N
    Biochem Biophys Res Commun; 1999 Apr; 257(3):719-23. PubMed ID: 10208850
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CGRP inhibits osteoprotegerin production in human osteoblast-like cells via cAMP/PKA-dependent pathway.
    Villa I; Mrak E; Rubinacci A; Ravasi F; Guidobono F
    Am J Physiol Cell Physiol; 2006 Sep; 291(3):C529-37. PubMed ID: 16611736
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of geranylgeranoic acid in bone: induction of osteoblast differentiation and inhibition of osteoclast formation.
    Wang X; Wu J; Shidoji Y; Muto Y; Ohishi N; Yagi K; Ikegami S; Shinki T; Udagawa N; Suda T; Ishimi Y
    J Bone Miner Res; 2002 Jan; 17(1):91-100. PubMed ID: 11771673
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Endogenous production of TGF-beta is essential for osteoclastogenesis induced by a combination of receptor activator of NF-kappa B ligand and macrophage-colony-stimulating factor.
    Kaneda T; Nojima T; Nakagawa M; Ogasawara A; Kaneko H; Sato T; Mano H; Kumegawa M; Hakeda Y
    J Immunol; 2000 Oct; 165(8):4254-63. PubMed ID: 11035059
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rolipram, a phosphodiesterase 4 inhibitor, suppresses PGE2-induced osteoclast formation by lowering osteoclast progenitor cell viability.
    Park H; Yim M
    Arch Pharm Res; 2007 Apr; 30(4):486-92. PubMed ID: 17489366
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Age of donor alters the effect of cyclic hydrostatic pressure on production by human macrophages and osteoblasts of sRANKL, OPG and RANK.
    Evans CE; Mylchreest S; Andrew JG
    BMC Musculoskelet Disord; 2006 Mar; 7():21. PubMed ID: 16519799
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lipopolysaccharide from Prevotella nigrescens stimulates osteoclastogenesis in cocultures of bone marrow mononuclear cells and primary osteoblasts.
    Chung YH; Chang EJ; Kim SJ; Kim HH; Kim HM; Lee SB; Ko JS
    J Periodontal Res; 2006 Aug; 41(4):288-96. PubMed ID: 16827722
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dual modulation of osteoclast differentiation by lipopolysaccharide.
    Zou W; Bar-Shavit Z
    J Bone Miner Res; 2002 Jul; 17(7):1211-8. PubMed ID: 12096834
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Secreted frizzled-related protein-1 inhibits RANKL-dependent osteoclast formation.
    Häusler KD; Horwood NJ; Chuman Y; Fisher JL; Ellis J; Martin TJ; Rubin JS; Gillespie MT
    J Bone Miner Res; 2004 Nov; 19(11):1873-81. PubMed ID: 15476588
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Alpha-lipoic acid suppresses osteoclastogenesis despite increasing the receptor activator of nuclear factor kappaB ligand/osteoprotegerin ratio in human bone marrow stromal cells.
    Koh JM; Lee YS; Byun CH; Chang EJ; Kim H; Kim YH; Kim HH; Kim GS
    J Endocrinol; 2005 Jun; 185(3):401-13. PubMed ID: 15930166
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Breast cancer increases osteoclastogenesis by secreting M-CSF and upregulating RANKL in stromal cells.
    Mancino AT; Klimberg VS; Yamamoto M; Manolagas SC; Abe E
    J Surg Res; 2001 Sep; 100(1):18-24. PubMed ID: 11516200
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.